These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 9696954)
21. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. Jorga K; Fotteler B; Sedek G; Nielsen T; Aitken J J Neurol; 1998 Apr; 245(4):223-30. PubMed ID: 9591224 [TBL] [Abstract][Full Text] [Related]
22. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease. Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690 [TBL] [Abstract][Full Text] [Related]
23. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Deleu D; Jacques M; Michotte Y; Ebinger G Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654 [TBL] [Abstract][Full Text] [Related]
24. The promise and limitations of controlled-release oral levodopa administration. Cedarbaum JM Clin Neuropharmacol; 1989 Jun; 12(3):147-66. PubMed ID: 2663145 [No Abstract] [Full Text] [Related]
25. Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients. Rainero I; Gilli M; De Gennaro T; Chiadò I; Delsedime M; Riccio A; Bergamasco B Ital J Neurol Sci; 1988 Jun; 9(3):255-9. PubMed ID: 3403218 [TBL] [Abstract][Full Text] [Related]
26. Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease. Greig SL; McKeage K CNS Drugs; 2016 Jan; 30(1):79-90. PubMed ID: 26692288 [TBL] [Abstract][Full Text] [Related]
27. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients]. García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023 [TBL] [Abstract][Full Text] [Related]
28. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. Contin M; Riva R; Martinelli P; Cortelli P; Albani F; Baruzzi A Clin Neuropharmacol; 1999; 22(6):351-5. PubMed ID: 10626097 [TBL] [Abstract][Full Text] [Related]
29. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease. Hutton JT; Morris JL Neurology; 1992 Jan; 42(1 Suppl 1):51-6; discussion 57-60. PubMed ID: 1549202 [TBL] [Abstract][Full Text] [Related]
30. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Metman LV; Hoff J; Mouradian MM; Chase TN Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216 [TBL] [Abstract][Full Text] [Related]
39. Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients. Stocchi F; Barbato L; Nordera G; Bolner A; Caraceni T J Neural Transm (Vienna); 2004 Feb; 111(2):173-80. PubMed ID: 14767720 [TBL] [Abstract][Full Text] [Related]
40. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety. Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]